MKNK2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL162573	0.52	19/20
SCHEMBL173840	0.50	16/20
SCHEMBL31554	0.63	15/20
SCHEMBL146532	0.51	13/20
SCHEMBL6026	0.55	12/20
SCHEMBL31555	0.62	11/20
SCHEMBL167082	0.58	10/20
SCHEMBL204513	0.51	9/20
SCHEMBL205583	0.51	9/20
SCHEMBL206263	0.71	8/20
SCHEMBL133437	0.58	8/20
SCHEMBL6027	0.58	8/20
SCHEMBL233227	0.53	8/20
SCHEMBL205967	0.53	8/20
SCHEMBL196216	0.52	8/20
SCHEMBL208351	1.00	7/20
SCHEMBL275492	0.41	6/20
SCHEMBL274499	0.40	6/20
SCHEMBL275870	0.40	6/20
SCHEMBL232042	1.00	5/20

Clinical trials — most relevant to MKNK2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer	PHASE2	COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
STAR Cape+BKM120 MBC With Brain Met	PHASE2	COMPLETED
Doxycycline in Human Pulmonary Tuberculosis	PHASE2	COMPLETED
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer	PHASE1	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212	PHASE1	COMPLETED
Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome	PHASE1	COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH)	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo	nan	UNKNOWN
Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation After Liver Transplantation	nan	COMPLETED
Rostock International Parkinson's Disease Study (ROPAD)	nan	COMPLETED
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a MKNK2 binder may also engage these)

Protein	Name	Similarity
Q5U2N4	—	1.000	Q5U2N4 →
MKNK1	MAP kinase-interacting serine/threonine-protein kinase 1	1.000	landscape →
Q8CDB0	—	0.998	Q8CDB0 →
Q4G050	—	0.998	Q4G050 →
O08605	—	0.997	O08605 →
Q66I46	—	0.993	Q66I46 →
Q66JF3	—	0.990	Q66JF3 →
Q0DCT8	—	0.990	Q0DCT8 →
Q6P431	—	0.989	Q6P431 →
PHKG2	Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	0.989	landscape →
Q9DB30	—	0.989	Q9DB30 →
Q9ZUZ2	—	0.988	Q9ZUZ2 →
Q7TNL3	—	0.988	Q7TNL3 →
Q58D94	—	0.988	Q58D94 →
Q17QV9	—	0.988	Q17QV9 →
Q39183	—	0.987	Q39183 →
A2YBX5	—	0.987	A2YBX5 →
Q9FG74	—	0.986	Q9FG74 →
Q6TJY3	—	0.986	Q6TJY3 →
Q7TNL4	—	0.986	Q7TNL4 →
RPS6KB1	Ribosomal protein S6 kinase beta-1	0.986	landscape →
Q5R667	—	0.986	Q5R667 →
Q8BSK8	—	0.985	Q8BSK8 →
Q9SUA3	—	0.985	Q9SUA3 →
CAMK4	Calcium/calmodulin-dependent protein kinase type IV	0.985	landscape →
Q9FIM9	—	0.984	Q9FIM9 →
Q2KJ16	—	0.984	Q2KJ16 →
O80673	—	0.984	O80673 →
Q39491	—	0.984	Q39491 →
Q64682	—	0.984	Q64682 →